Prevention of acute GVHD by in vivo use of anti-interleukin-2 receptor monoclonal antibody (33B3.1): a feasibility trial in 15 patients. - Blaise,D.; Olive,D.; Hirn,M.; Viens,P.; Lafage,M.; Attal,M.; Stoppa,A.M.; Gabert,J.; Gastaut,J.A.; Camerlo,J.; Mannoni,P.; Mawas,C.; et al. (Bone Marrow Transplant, 1991)